ARENA PHARMACEUTICALS INC Form 8-K October 28, 2008

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 28, 2008

Arena Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

Delaware 000-31161 23-2908305

23-2908305

(State or other jurisdiction of incorporation)

(Commission File Number)

(I.R.S. Employer Identification No.)

6166 Nancy Ridge Drive, San Diego, California 92121

(Address of principal executive offices) (Zip Code)


858.453.7200

23-2908305

(Registrant s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)



23-2908305

In this report, Arena Pharmaceuticals,	Arena,	we,	us	and	our	refer to Arena Pharmaceuticals, Inc. and its wholly owned subsidiaries, unless
context otherwise provides.						

Item 8.01 Other Events.

Collaboration updates

Merck & Co., Inc. has completed a Phase 1 program of a second generation oral niacin receptor agonist under its collaboration with us to discover drugs for the treatment of atherosclerosis and other disorders. Having evaluated safety, tolerability and pharmacokinetics in this randomized, double-blind, placebo-controlled program, Merck is planning to initiate a Phase 2 clinical program in the first half of 2009.

Based on data from preclinical studies, Taisho Pharmaceutical Co., Ltd. discontinued a Phase 1 clinical trial of a drug candidate intended for the treatment of a common psychiatric disorder, which was being developed under its partnership with us.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: October 28, 2008 Arena Pharmaceuticals, Inc.

By: /s/ Jack Lief Jack Lief

President and Chief Executive Officer

2

23-2908305 4